Aripiprazole versus other atypical antipsychotics for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Khanna, Priya ^a   Suo, Tao ^b   Komossa, Katja ^c   Ma, Huaixing ^b   Rummel Kluge, Christine ^d   El Sayeh, Hany George ^e   Leucht, Stefan ^f   Xia, Jun ^g  

^a TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e HARROGATE DISTRICT HOSPITAL   (United Kingdom)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g Systematic Review Solutions   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AKATHISIA; BODY WEIGHT; CENTRAL NERVOUS SYSTEM DISEASE; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METABOLIC DISORDER; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QTC INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; META ANALYSIS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84903815492     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006569.pub5     Document Type: Review

References (173)

1. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, et al.Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. Journal of Clinical Psychiatry 2007;68(1):29-36.
2. Hwang TJ, Chan HY, Lin WW, Lin SK, Hwu HG, Cheng MY, et al.Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. Journal of the European College of Neuropsychopharmacology 2005;14(Suppl 3):S497.
3. Fan W-L, Yu C-M, Wen J-S. Efficacy analysis of aripiprazole and clozapine in the treatment of schizophrenia. Journal of North Sichuan Medical College 2005;20(4):377-9.
4. BMS . A multicenter, double-blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia. Clinical Study Report CN138003 2005.
5. Han P, Zhang Y-H, Zhang C-Z. Quality of life in schizophrenics treated with aripiprazole or clozapine. Chinese Journal of Rehabilitation Theory and Practice 2006;12(12):995-6.
6. Jiang G, Luo J. Aripiprazole and clozapine in treatment refractory schizophrenia randomized controlled study] Google Translate. Chongqing Medical Journal 2009;38(1):87-8.
7. Jie R, Wang G. Aripiprazole and clozapine treatment of schizophrenia with predominantly negative symptoms. Sichuan Mental Health 2008;21(2):107-9.
8. Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, et al.Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion 2011;27(1):115-22.
9. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Biological Psychiatry 2008;63(7 Suppl):289S.
10. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. 2008.
11. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, et al.A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Journal of Clinical Psychiatry 2009;70(4):572-81. [MEDLINE: 19323965]
12. Osuntokun O, Kane JM, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2008;11(Suppl 1):153.
13. Watson SB, Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
14. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al.The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 2006;187(3):312-20.
15. Beuzen JN, L'Italien G, Hanssens L, Marcus RN, McQuade RD, Carson WH. Changes in prolactin levels and arizona sexual experience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the schizophrenia trial of aripiprazole (STAR) study. Schizophrenia Bulletin 2007;33(2):421-2.
16. Blonde L, Kan HJ, Gutterman EM, L'Italien GJ, Kim MS, Hanssens L, et al.Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Journal of Clinical Psychiatry 2008;69(5):741-8. [MEDLINE: 18435564]
17. Hanssens L, L'Italien G, Marcus RN, McQuade RD, Carson WH, Beuzen JN. Reasons for switching from previous therapy and preference of medication in the large, randomized, naturalistic schizophrenia trial of aripiprazole (STAR). Schizophrenia Bulletin 2007;33(2):432.
18. Hanssens L, L' Italien G, McQuade R, Iwamoto T, Pans M. Evaluation of quality of life in community-treated schizophrenic patients: a naturalistic, open-label study comparing aripiprazole to standard-of-care (Schizophrenia Trial of aripiprazole: STAR study). European Psychiatry 2006;21(Suppl 1):S99.
19. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al.A multi centre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of aripiprazole: (STAR) study. European Psychiatry 2007;22(7):433-43. [MEDLINE: 17555947]
20. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al.A multi centre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenic Trial of aripiprazole: (STAR) study. Wiadomosci Psychiatryczne 2008;11(2):105-19.
21. King D, Knapp M, Thomas P, Razzouk D, Loze JY, Kan HJ, et al.Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: Star study. Current Medical Research and Opinion 2011;27(2):365-74.
22. Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD. Changes in weight and weight-related quality of life in a multi centre, randomized trial of aripiprazole versus standard of care. European Psychiatry 2008;23(8):561-6. [MEDLINE: 18374544]
23. L'Italien G, Hanssens L, Kan HJ, Baker RA, Marcus RN, McQuade RD, et al.Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the STAR trial). Schizophrenia Bulletin 2007;33(2):439.
24. L'Italien GJ, Blonde L, Hanssens L, McQuade R. Prevalence of diabetes/cardiovascular risk factors among schizophrenia patients treated with atypical antipsychotics in a multicenter, randomized, naturalistic, open-label study (Schizophrenia Trial of aripiprazole: STAR study). Diabetes 2006;55(Suppl 1):A538.
25. L'ltalien GJ, Hanssens L, Marcus RN, McQuade RD. Evidence of antipsychotic treatment selection based on metabolic risk factors among community-based schizophrenia patients (The STAR Trial). Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007.
26. Millet B. A multicenter, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients (Schizophrenia Trial of aripiprazole - STAR). http://www.clinicaltrials.gov 2005.
27. Taylor D, Hanssens L, Loze J-Y, Pans M, L'Italien G, Marcus RN. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry 2008;23(5):336-43.
28. Eli Lilly, Company . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry 2004.
29. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology 2008;28(6):601-7. [MEDLINE: 19011427]
30. Stauffer V, Kinon B, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
31. Li M, Wu N, Li Y-F. Comparative study of influence of aripiprazole on life quality in schizophrenic patients. Chinese Journal of Health Psychology 2007;15(10):956-7.[MEDLINE:].
32. Li Q, Li G, Li G. Effects of aripiprazole and clozapine on life quality of schizophrenics. Journal of Clinical Psychosomatic Diseases 2007;13(5):404-6.[MEDLINE: ].
33. Mai G-Y, Cai G-H, Huang J-M. Comparative study on the effect of aripiprazole and risperidone on schizophrenia. Chinese Journal of Rehabilitation, 2005;20(3):184-5.
34. Abou Gharbia N, McQuade R, Jody D, Kujawa M, Carson W, Iwamoto T, et al.Comparative study of the long-term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy. 2004.
35. Blonde L, Ray S, Corey-Lisle PK, Cislo PR, L'Italien G. The risk of new-onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S275.
36. Jody D, McQuade RD, Kujawa M, Carson W, Iwamoto T, Archibald D, et al.Long-term weight effects of aripiprazole versus olanzapine. Schizophrenia Research 2004;67(1):187.
37. McQuade RD, Jody D, Kujawa MJ, Carson WH, Iwamoto T, Archibald DG, et al.Long-term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003.
38. McQuade RD, Kujawa M, Saha AR, Ingenito GG, Ali MW, Luo X, et al.Aripiprazole for long-term maintenance treatment of schizophrenia. Schizophrenia Research 2003;60(1):295.
39. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al.A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. Journal of Clinical Psychiatry 2004;65(Suppl 18):47-56. [MEDLINE: 15600384]
40. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al.A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. Journal of Clinical Psychiatry 2004;65(Suppl 18):47-56.
41. Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Journal of Clinical Psychiatry 2009;70(3):318-25. [MEDLINE: 19192469]
42. Potkin SG, Kujawa M, Carson WH, Saha AR, Ali M, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research 2003;60:300.
43. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al.Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2003;60(7):681-90.
44. Riera L, Hu R, Stock E, Nyilas M, Torbeyns A, Borian F, et al.Broad effectiveness trial with aripiprazole. Schizophrenia Research 2004;67(1):157.
45. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al.A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With aripiprazole (BETA). Schizophrenia Research 2006;84(1):77-89.
46. Sanchez R, Kostic D, Stock E, Torbeyns AF, Kerselaers W, Nyilas M, et al.Aripiprazole vs olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week open-label extension study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
47. Wlodzimierz CK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189(2):259-66.
48. Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamato T, et al.Broad effectiveness trial with aripiprazole in Europe Eu-Beta. Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2-6; Munich, Germany. 2005.
49. Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, et al.Naturalistic study of aripiprazole treatment. Proceedings of the XIII World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt. 2005.
50. Beuzen J-N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, et al.Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
51. Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al.A prospective, multi centre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with aripiprazole in Europe (EU-BETA). Current Medical Research and Opinion 2007;23(10):2313-23. [MEDLINE: 17706003]
52. Zhu P-J, Cheng Z-E, Zhang J, Zhu P-L, Zhan X-M. Clinical study of therapeutic effects of aripiprazole in treatment of patients with schizophrenia. Chinese Journal of Clinical Pharmacology and Therapeutics 2005;10(10):1194-7.
53. Pfizer . A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov 2008.
54. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study. International Clinical Psychopharmacology 2007;22(6):363-70. [MEDLINE: 17917555]
55. Allen M, Talbott S, Eudicone J, McQuade R, Pikalov A. Similar rates of agitation, anxiety and insomnia in sedating and non-sedating antipsychotics: evaluating clinical trial results with aripiprazole, haloperidol and olanzapine. Schizophrenia Bulletin 2007;33(2):418.
56. Anon . Effectiveness of antipsychotic combination with psychosocial intervention on outcome of patients with schizophrenia. http://www.clinicaltrials.gov 2008.
57. Bergman M, Friedman JI, Stawarz K, Bowman A, Siever L, Cavagna M, et al.A double blind placebo controlled study of guanfacine adjunctive treatment to atypical antipsychotics for cognitive dysfunction in schizophrenia. http://www.clinicaltrials.gov 2007.
58. Bristol-Myers Squibb, Otsuka America Pharmaceutical. A multicenter, randomized, double-blind, placebo-controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder demonstrating an inadequate response to quetiapine or risperidone monotherapy. http://www.clinicaltrials.gov 2006.
59. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology 2000;10(Suppl 3):S309.
60. Casey D, L'Italien G, Waldeck R, Cislo P, Carson W. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17- 22; San Francisco, California, USA. 2003.
61. Chen J-D, Zhao J-P, Li L-H, Guo X-F, Zhai J-G, Wang C-Y, et al.A multi centre, randomised and double-blind controlled trial of aripiprazole in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2005;11:845-8.
62. Colombo GL, Caruggi M, Di Matteo S, Rossi A. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatric Disease and Treatment 2008;4(5):967-76.
63. Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G, et al.Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophrenia Research 2002;53(3 Suppl 1):27.
64. Fawzi M, Fawzi M Jr. Aripiprazole, olanzapine and olanzapine-clomipramine combination in schizophrenia with obsessive-compulsive symptoms. World Psychiatry 2009;8(Suppl 1):NRS5.4.
65. Fleischhacker W, Heikkinen ME, Olie JP, Dewaele P, McQuade R, Hennicken D, et al.Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine. European Neuropsychopharmacology 2008;18:S447.
66. Markovic O. A multicenter, comparative, randomized, double-blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. http://www.clinicaltrials.gov 2006.
67. Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, et al.Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Research 2009;113(1):49-55.
68. Henderson DC, Fan X, Copeland PM, Borba CP, Freudenreich O, Evins AE, et al.Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology 2009;29(2):165-9.
69. Roussel JJ, Machon DA, Henderson DC. A placebo-controlled, cross-over trial of aripiprazole added to obese olanzapine-treated patients with schizophrenia. http://www.clinicaltrials.gov 2006.
70. Kim YS. A double-blind randomized placebo controlled study of aripiprazole augmentation for clozapine-treated patients with refractory schizophrenia. http://www.clinicaltrials.gov 2006.
71. Kim C-Y. A multi-center, randomized, open, treatment-switching study from orally administered antipsychotic monotherapy in the treatment of chronic schizophrenic and schizoaffective patients. http://www.clinicaltrials.gov 2006.
72. Kim CY, Chung S, Lee JN, Kwon JS, Kim DH, Kim CE, et al.A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology 2009;24(4):181-8. [MEDLINE: 19451828]
73. Lan T, Chiu H, Hu T, Huang H, Wu B, Tuan Y. Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia. European Neuropsychopharmacology 2008;18:S440.
74. Medori R, Wapenaar R, De Arce R, Rouillon F, Gaebel W, Cordes J, et al.Relapse prevention and effectiveness in schizophrenia of risperidone long-acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
75. Millar H, Felter C, Landsberg W. The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170). Journal of Psychopharmacology 2008;22(5):A17.
76. Mortimer AMP. Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence-Based Mental Health 2004;7(2):41. [MEDLINE: 15107337]
77. Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al.Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics 2009;19(1):91-4. [MEDLINE: 18849890]
78. Namey LB, Henderson DC. Aripiprazole for clozapine associated medical morbidity. http://www.clinicaltrials.gov 2006.
79. Newcomer JW, L'Italien G, Vester-Blokland, McQuade RD, Carson WH, Marcus RN. Improvement of non-hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006.
80. Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, et al.Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia Research 2008;106(2-3):300-7.
81. Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, et al.Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia Research 2008;106(2-3):300-7.
82. Pae CU, Serretti A, Chiesa A, Mandelli L, Lee C, Kim J, et al.Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology 2009;19(8):562-70.
83. Ray S, Corey-Lisle PK, Cislo PR, L'Italien G, Weiden P. An economic evaluation of aripiprazole compared to olanzapine based on metabolic side-effect profile. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S279.
84. Remington G. Refractory schizophrenia: Adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence-Based Mental Health 2009;12(2):51.
85. Schreiner A, De Arce R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, et al.Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28-Jul 2; Paris, France. 2009.
86. Shim JC, Kelly DL, Jung DU, Seo YS, Kim YH, Conley RR. Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia. European Neuropsychopharmacology 2006;16(Suppl 4):S405.
87. Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, et al.A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. Journal of Clinical Psychopharmacology 2008;28(5):540-3.
88. Talbott S, Buckley P, Eudicone J, McQuade R, Van-Tran Q. Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine-analyses of the first 12 weeks of three double-blind, long-term trials. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA 2007.
89. Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-Based Mental Health 2007;10(3):76. [MEDLINE: 17652558]
90. Watts KL, Wilson H, Tang T. Estimating and reducing the cardiovascular risk of patients with schizophrenia drugs from lipid measures and ischemic electrocardiographic changes. http://www.clinicaltrials.gov 2006.
91. Yang S, Gao S, Wu X. A control study of aripiprazole vs. clozapine in the treatment of refractory schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(1):15-6.
92. Bristol-Myers Squibb. Metabolic abnormalities - OPT. http://www.clinicaltrials.gov 2009.
93. Eli Lilly, Company . Study of olanzapine vs aripiprazole in the treatment of schizophrenia. Eli Lilly and Company Clinical Trial Registry 2003.
94. Essock SM, Covell NH, Carbuto M, Bielen K, Jabbour B, Saltz BL, et al.Effectiveness of switching antipsychotic medications. http://www.clinicaltrials.gov 2002.
95. Glorioso DK, Jeste DV. Metabolic effects of newer antipsychotics in older patients. http://www.clinicaltrials.gov 2005.
96. Hanssens L. A 16-Week, multicenter, randomized, open-label study to assess the effects of aripiprazole versus other atypical antipsychotics in the treatment of schizophrenic patients with metabolic syndrome. http://www.clinicaltrials.gov 2007.
97. Johnson & Johnson Pharmaceutical Research & Development LLC. A 2-year, prospective, blinded-rater, open-label, active-controlled, multicenter, randomized study of long-term efficacy and effectiveness comparing risperdal® consta® and abilify® (aripiprazole) in adults with schizophrenia. http://www.clinicaltrials.gov 2006.
98. Lehrer DS, Jewell M. Best event schizophrenia trial--a randomized double-blind trial of aripiprazole and risperidone in schizophrenia. http://www.clinicaltrials.gov 2008.
99. Lin C-C. Identification and treatment response prediction of antipsychotic-related metabolic syndrome. http://www.clinicaltrials.gov 2009.
100. Livingston M, Stroup TS, McEvoy JP, Rojas I, Gamel N, Glick I, et al.Clinical management of metabolic problems in patients with schizophrenia. http://www.clinicaltrials.gov 2007.
101. McCormack J, Robinson D, Tobias K, Petrides G, Robinson D, Sevy S, et al.Preventing morbidity in first episode schizophrenia, part II. http://www.clinicaltrials.gov 2006.
102. McEvoy JP. Metabolic signatures and biomarkers for aripiprazole. http://www.clinicaltrials.gov 2007.
103. Montoya D, Blizard R, Buckley PF, Holman T, Kerr J, Miller DD, et al.Preventing relapse: oral antipsychotics compared to injectables: evaluating efficacy (PROACTIVE). http://www.clinicaltrials.gov 2006.
104. Schweiger J, Flavin K, Rosen B, Spies A, Newcomer JW, Haupt D. Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics. http://www.clinicaltrials.gov 2005.
105. Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA. Comparison of antipsychotics for metabolic problems (CAMP): a NIMH schizophrenia trials network study. Clinical Schizophrenia and Related Psychoses 2007;1(1):69-72.
106. Swartz M, Stroup TS, McEvoy JP, Rojas IA. Comparison of optimal antipsychotic treatments for adults with schizophrenia. http://www.clinicaltrials.gov 2008.
107. Vontur MG, Lopez J, Woolsey MD, Maples NL, Velligan DI. Do patients taking aripiprazole learn more in vocational skills training than patients taking olanzapine?. http://www.clinicaltrials.gov 2005.
108. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
109. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2nd Edition. American Psychiatric Publishing, Inc, 2004:1-114.
110. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
111. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
112. Belgamwar Ravindra B, El-Sayeh Hany George G. Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: ]
113. Bhattacharjee J, El-Sayeh Hany George G. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: ]
114. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
115. British National Formulary (BNF). http://www.bnf.org/bnf/index.htm accessed June/July 2013.
116. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, et al.The problem of therapeutic efficacy indices.3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
117. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
118. Chaichan W. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p. r. n. medication. Journal of Psychiatric Practice 2008;14(2):105-13. [PUBMED: 18360196]
119. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: ]
120. Deeks J. Issues in the selection for meta-analyses of binary data. Proceeding of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000.
121. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
122. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
123. Duggan L, Dardennes R, El-Dosoky A, Fenton M, Indran S, Rathbone J. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: ]
124. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
125. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: ]
126. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
127. U. S. Federal Drug Administration CDER. Abilify (aripiprazole) tablets, medical review. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002 (accessed 18 August 2006).
128. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
129. Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf 2006.
130. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
131. Guy U. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, 1976.
132. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10(3):388-98. [PUBMED: 6474101]
133. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185-94.
134. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
135. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
136. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
137. Jelsma J, Mhundwa K, De Weerdt W, De Cock P, Chimera J, Chivaura V. The reliability of the Shona version of the EQ-5D. Central African Journal of Medicine 2001;47(1):8-13. [PUBMED: 11961858]
138. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al.Randomized controlled trial of the effect on quality of life. Archives of General Psychiatry 2006;63:1079-6.
139. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96.
140. Kane JM. Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585-93.
141. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
142. Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample. Quality of Life Research 2002;11(2):157-71. [PUBMED: 12018739]
143. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
144. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
145. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
146. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al.A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166(2):152-63. [DOI: ]
147. Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
148. Maayan N, Soares-Weiser K, Xia J, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: ]
149. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
150. Martindale: the complete drug reference. http://www.medicinescomplete.com/mc/martindale/current/ accessed June/ July 2013.
151. Marvaha S, Johnson S. Schizophrenia and employment - a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
152. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al.The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sex & Marital Therapy 2000;26(1):25-40. [PUBMED: 10693114]
153. Moher D, Schulz KF, Altman D. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel- group randomized trials. JAMA 2001;285:1987-1.
154. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: ;: CD006629]
155. Möller HJ. New assessment of atypical antipsychotics [Aktuelle bewertung neuer/atypischer neuroleptika]. Nervenarzt 2000;71:329-44.
156. O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Quality of Life Research 2000;9:121-4.
157. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
158. Pagadala B, Jayaram Mahesh B, Mitra L. Aripiprazole for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: ]
159. Rivas-Vasquez RA. Aripiprazole: A novel antipsychotic with dopamine stabilising properties. Professional Psychology 2003;34(1):108-11.
160. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
161. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
162. Simpson EN, Angus JWF. A rating scale for extrapyramidal adverse effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
163. Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, et al.Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Research 2005;136(2-3):211-21. [PUBMED: 16115690]
164. Tandon R, Keshavan MS, Nasralllah HA. Schizophrenia, "just the facts"What we know in 2008.2. Epidemiology and etiology. Schizophrenia Research 2008;102:1-18.
165. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al.A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology 2009;62(5):464-75. [PUBMED: 19348971]
166. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
167. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
168. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: ; PUBMED: 12076447]
169. WHO . The World Health Report 2001 - Mental Health: New Understanding, New Hope. Geneva: World Health Organization, 2001.
170. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.The Leeds Outcomes Stakeholders Survey (LOSS) study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007. 2007.
171. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
172. Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh HG, et al.Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: ]
173. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, et al.Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: ; PUBMED: 19821375]